Fireman B.V.

General Information

We are a clinical-stage biopharmaceutical company focused on applying our proprietary anti-C5a technology to discover and develop first-in-class potent and specific inhibitors of the complement activation factor known as C5a. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Our lead product candidate, IFX-1, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Employees: 17
Founded: 2017
Contact Information
Address Winzerlaer Str. 2, 07745 Jena, Germany
Phone Number (+49) 3641 508180.
Web Address
View Prospectus: Fireman B.V.
Financial Information
Market Cap $351.2mil
Revenues $0.2 mil (last 12 months)
Net Income $-15.0 mil (last 12 months)
IPO Profile
Symbol IFRX
Exchange NASDAQ
Shares (millions): 6.7
Price range $15.00 - $15.00
Est. $ Volume $100.0 mil
Manager / Joint Managers J.P. Morgan/ Leerink Partners/ BMO Capital Markets
CO-Managers -
Expected To Trade: 11/8/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change